Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: A comparative analysis using clinical trial and drug utilization data

American Journal of Cardiovascular Drugs

Volumn 10, Issue 1, 2010, Pages 49-54

  Boersma, Cornelis ^a   Voors, Adriaan A ^b   Visser, Sipke T ^a   De Jong Van Den Berg, Lolkje T W ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiotensin receptor antagonists, therapeutic use; Cost effectiveness; Hypertension, treatment; Irbesartan, therapeutic use; Losartan, therapeutic use; Olmesartan medoxomil, therapeutic use; Valsartan, therapeutic use

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; ESSENTIAL HYPERTENSION; FEMALE; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NETHERLANDS; OUTCOME ASSESSMENT; PHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; MODELS, ECONOMIC; NETHERLANDS;

EID: 77149122711     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11319570-000000000-00000     Document Type: Article

References (33)

1. Slobbe LCJ, Kommer GJ, Smit JM, et al. Kosten van ziekten in Nederland 2003. Zorg voor euro's -1. Bilthoven: RIVM, Centrum voor Volksgezondheid en Toekomst Verkenningen, 2006
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275 (20): 1571-1576
3. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757
4. Scheltens T, Bots ML, Numans ME, et al. Awareness, treatment and control of hypertension: the 'rules of halves' in an era of risk-based treatment of hypertension. J Hum Hypertens 2007; 21: 99-106
5. Chobanian AV, Bakris GL, Black HR, et al., and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-2572
6. Withworth JA. World Health Organization, International Society of HypertensionWriting Group: 2003World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983-1992
7. Mancia G, De Backer G, Dominizak A, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007 guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462-1536
8. NHG-Standaard: cardiovasculair risicomanagement (M84). 2007 version [online]. Available fromURL: http://nhg.artsennet.nl/kenniscentrum/k- richtlijnen/k-nhg standaarden/Samenvattingskaartje-NHGStandaard/M84-svk.htm [Accessed 2009 Oct 8]
9. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21 (1): 23-33 (Pubitemid 29355511)
10. Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999; 53 (3): 175-178
11. Okereke CE, Messerli FH. Efficacy and safety of angiotensin II receptor blockers in elderly patients with mild to moderate hypertension. AmJ Geriatr Cardiol 2001; 10 (1): 42-49
12. Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis 2006; 49 (1): 16-25
13. InterAction DataBase project (IADB.nl) [online]. Available from URL: http://www.iadb.nl [Accessed 2008 Jul 16]
14. Schirm E, Monster TBM, de Vries R, et al. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information. Pharmacoepidemiol Drug Saf 2004; 13: 173-179
15. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin. Hypertens 2001; 3 (5): 283-291
16. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004; 363: 1728-1731
17. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PloS Med 2008; 5 (3): 339-343
18. Tannen RL, Weiner MG, Xie D.Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009; 338: b81
19. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD Index 2005 [online]. Available from URL: http://www.whocc.no/atcddd [Accessed 2007 Oct 8]
20. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 2005; 18: 287-294
21. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298
22. Odell PM, Anderson KM, Kannel WB. New models for predicting cardiovascular events. J Clin Epidemiol 1994; 47 (6): 583-592
23. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting. Olmesartan medoxomil compared with losartan, valsartan, and irbesartan. Pharmacoeconomics 2003; 21 (1): 61-74
24. Boersma C, Radeva JI, Koopmanschap MA, et al. Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to the Netherlands. J Med Econ 2006; 9: 121-131
25. Atthobari J, Asselbergs FW, Boersma C, et al., for the PREVEND-IT Study Group. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the Prevention of REnal and Vascular ENdstage Disease (PREVEND) study and the Prevention of REnal and Vascular ENdstage Disease Intervention Trial (PREVEND-IT). Clin Ther 2006; 28: 432-444
26. Z-index Taxe, G-standaard [CD-ROM]. The Hague: Z-Index BV, 2006 Oct
27. Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie. Diemen: College voor zorgverzekeringen, 2006
28. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16 (8): 569-575
29. GIPdatabank. Amsterdam: College voor zorgverzekeringen (CVZ), 2008 [online]. Available from URL: http://www.gipdatabank.nl/ [Accessed 2008 Jul 16]
30. Conlin PR, Spence JD,Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426
31. Püchler K, Laeis P, Stumpe K. Blood pressure response, but not adverse event incidence correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 Suppl. 1: S41-8
32. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 Suppl. 2: S24-8
33. Stumpe KO. Olmesartan compared to other angiotensin II antagonists: headto-head trials. Clin Ther 2004; 26 Suppl. A: A33-7